Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.00    -0.50 (-0.75%)
Bid:
65.00
Ask:
67.00
Spread: 2.00 (3.077%)
Market Cap: £80.07m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

Director/PDMR Shareholding

Today 15:03

RNS Number : 4429K
Venture Life Group PLC
30 June 2026
 

30 June 2026

VENTURE LIFE GROUP PLC

("Venture Life", "VLG" or the "Company")

Director/PDMR Shareholding

Venture Life (AIM: VLG), a recognised leader in proactive longevity, health innovation and global commercialisation within the global consumer healthcare sector, announces that Paul McGreevy, Non-Executive Chairman, has today purchased 93,887 ordinary shares of 0.3 pence each in the capital of the Company ("Ordinary Shares") at a volume-weighted average price of 63.9 pence per Ordinary Share.

Following the purchase, Mr McGreevy beneficially holds 1,145,985 Ordinary Shares representing approximately 0.89 per cent. of the Company's issued share capital.

 

For further information, please contact:

 

Venture Life Group PLC

+44 (0) 1344 578004

Jerry Randall, Chief Executive Officer

Daniel Wells, Chief Financial Officer

 

Cavendish Capital Markets Limited (Nomad and Broker)

 

+44 (0) 20 7720 0500

Stephen Keys / George Lawson (Corporate Finance)

Michael Johnson (Sales)

 

 

About Venture Life (www.venture-life.com)

Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners. 

 

The Company makes the following disclosure in accordance with article 19(3) of the Market Abuse Regulation:

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Paul McGreevy

2

 

Reason for the notification

 

a)

 

Position/status

 

Non-Executive Chairman

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Venture Life Group plc

b)

 

LEI

 

213800S8CZUPLAB2KC70

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 

Identification code

 

Ordinary Shares of 0.3p each in Venture Life Group plc

 

 

 

GB00BFPM8908

b)

 

Nature of the transaction

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price

Volume

63.875 pence

31,297

63.875 pence

31,297

63.850 pence

15,650

63.880 pence

15,643

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

93,887 Ordinary Shares purchased at a volume-weighted average price of 63.9 pence.

 

 

e)

 

Date of the transaction

 

30 June 2026

f)

 

Place of the transaction

 

London Stock Exchange

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFLFISRLIIVIR
Date   Source Headline
2nd Sep 202410:41 amRNSDirector/PDMR Shareholding
2nd Sep 202410:40 amRNSReplacement - Exercise of Options & TVR
23rd Aug 20247:00 amRNSExercise of Options, Director Dealings & TVR
9th Aug 20241:17 pmRNSHolding(s) in Company
6th Aug 20247:00 amRNSTrading Update
25th Jul 20243:54 pmRNSHolding(s) in Company
11th Jul 202410:08 amRNSHolding(s) in Company
19th Jun 20242:46 pmRNSPosting of Annual Report
4th Jun 20243:34 pmRNSResult of AGM
4th Jun 20247:00 amRNSAGM Statement
23rd May 202411:35 amRNSExercise of Share Options & Total Voting Rights
19th Apr 20247:00 amRNSRCF in Place and New Partner in the USA
9th Apr 20247:00 amRNSFinal Results for year ended 31 December 2023
4th Apr 20247:00 amRNSNotice of Results and Investor Presentation
19th Feb 20245:18 pmRNSHolding(s) in Company
6th Feb 202410:48 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSTrading Update
20th Dec 20232:00 pmRNSHolding(s) in Company
28th Nov 202312:28 pmRNSHolding(s) in Company
22nd Nov 20234:05 pmRNSHolding(s) in Company
14th Nov 20237:00 amRNSChange of Nominated Adviser and Broker
31st Oct 20233:11 pmRNSHolding(s) in Company
17th Oct 20231:54 pmRNSHolding(s) in Company
25th Sep 20237:01 amRNSDirector/PDMR Shareholding
25th Sep 20237:00 amRNSHalf-year Report
5th Sep 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSTrading Statement
5th Jul 20237:00 amRNSPDMR Shareholdings – Grant of Awards
26th Jun 20234:48 pmRNSDirector/PDMR Shareholding
25th May 20231:54 pmRNSDirector Dealings
22nd May 20233:01 pmRNSResults of AGM
22nd May 20237:00 amRNSAGM Statement
19th May 20237:00 amRNSBoard Change
9th May 20237:00 amRNSNotice of Capital Markets Event
28th Apr 202310:05 amRNSAnnual Report and Notice of AGM
5th Apr 20231:53 pmRNSDirector/PDMR Shareholding
4th Apr 20237:00 amRNSFinal Results for year ended 31 December 2022
31st Mar 20237:00 amRNSInvestor Presentation
13th Mar 20237:00 amRNSUpdate re Revolving Credit Facility
10th Mar 20232:05 pmRNSSecond Price Monitoring Extn
10th Mar 20232:00 pmRNSPrice Monitoring Extension
31st Jan 20237:00 amRNSTrading Statement
9th Jan 20237:00 amRNSLicensing and distribution agreements
1st Dec 20224:41 pmRNSSecond Price Monitoring Extn
1st Dec 20224:37 pmRNSPrice Monitoring Extension
1st Dec 20227:00 amRNSAcquisition and trading update
10th Oct 20227:00 amRNSDirectorate Changes
23rd Sep 202211:08 amRNSInvestor Presentation
22nd Sep 20227:00 amRNSHalf-year Report
25th Jul 202212:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.